Clinical Trials
A-DREAM Supports Treatment Interruption for Select Exceptional Responders With mHSPC

article
A Strategy to Reduce the Burden of Continuous Therapy
For patients with metastatic hormone-sensitive prostate cancer (mHSPC), androgen-deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) improves disease control but can create cumulative toxicity and cost when continued indefinitely. The phase 2 A-DREAM study (Alliance A032101) evaluated whether carefully selected patients with an exceptional biochemical response could safely pause both treatments and experience a meaningful treatment-free interval with testosterone recovery.
Study Design Focused on Exceptional Responders
The single-arm trial enrolled 78 eligible patients with metastatic disease confirmed by conventional imaging. Participants had received ADT for 18 to 24 months and an ARPI for at least 12 months, with prostate-specific antigen (PSA) <0.2 ng/mL and stable or falling before treatment interruption. The median age was 70 years; 35.1% had high-volume disease and 64.9% had low-volume disease.
After ADT and ARPI were stopped, PSA and testosterone were assessed every 3 months, with imaging at least every 6 months and quality-of-life evaluation every 6 months. Protocol-defined triggers for restarting treatment included PSA of at least 5 ng/mL, radiographic progression, or prostate cancer–related symptoms. The primary end point was the proportion of patients who remained treatment-free and achieved testosterone recovery to at least 150 ng/dL at 18 months.
Primary End Point Met
At 18 months, 52 patients (66.7%) had recovered testosterone, 45 (57.7%) remained treatment-free, and 32 (41.0%) met both components of the primary end point. These findings met the study’s prespecified objective and demonstrated that a substantial subgroup of exceptional responders can remain off systemic therapy while recovering testosterone.
With a median follow-up of 26.9 months, 30 patients (38.5%) continued treatment interruption. The estimated median duration off treatment was 24.5 months. Among those who restarted protocol therapy after meeting reinitiation criteria, a small number subsequently developed radiographic progression. Exploratory analyses suggested that low-volume disease and prior radiation therapy were associated with a lower likelihood of requiring treatment restart, although these findings should be interpreted cautiously.
Limitations and Next Steps
Interpretation is limited by the single-arm design, absence of a comparator, modest sample size, and selection of patients and clinicians willing to interrupt therapy. Some patients resumed or changed treatment outside protocol-defined criteria, and the relationship between the primary end point and long-term outcomes remains uncertain. Longer follow-up is needed for radiographic progression-free survival, overall survival, quality of life, and cost outcomes. Biomarker and patient-reported outcome analyses are also ongoing.
Practice Takeaway
For exceptional responders to ADT plus an ARPI, A-DREAM shows that a monitored treatment interruption can produce sustained time off therapy with testosterone recovery. The results support shared decision-making about treatment holidays in carefully selected patients, while reinforcing the need for rigorous surveillance and further study of optimal intermittent strategies.
Sources
Choudhury AD, Ballman KV, Reimers MA, et al. A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101). Presented at: 2026 American Society of Clinical Oncology Annual Meeting. Abstract 5004. Slide presentation.
Choudhury AD, Ballman KV, Reimers MA, et al. A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101). J Clin Oncol. 2026;44(suppl). Abstract 5004. doi:10.1200/JCO.2026.44.16_suppl.5004


